SCHEDULE: Tevogen Bio CEO Ryan Saadi Boosts Stake with New Stock Grant Amidst Recent Share Sale

Tevogen Bio Holdings Inc. CEO Ryan Saadi increased his beneficial ownership to 64.5% with a new 8 million share restricted stock grant, while also disclosing a recent sale of over 1.4 million shares.

Summary

• Ryan H. Saadi, CEO of Tevogen Bio Holdings Inc., beneficially owns 125,008,376.32 shares, representing 64.5% of the company's Common Stock outstanding as of July 10, 2025.
• This includes 27,348,954 shares of restricted Common Stock that carry voting rights but are subject to transfer restrictions and forfeiture.
• On June 27, 2025, Mr. Saadi received a grant of 8,000,000 shares of Restricted Stock as compensation for his service as Chief Executive Officer.
• These newly granted shares vest in four equal annual installments starting on June 27, 2032, contingent on continuous service, with accelerated vesting upon death or disability.
• On June 9, 2025, Mr. Saadi sold 1,438,206 shares of Common Stock in an open market transaction at a volume-weighted average price of $1.23 per share, with prices ranging from $1.10 to $1.425.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the CEO's significant open market share sale, which can signal a lack of confidence or a need for liquidity. While a large restricted stock grant was issued, its extremely long vesting period (starting 7 years out) diminishes its immediate positive impact on sentiment, as it does not immediately align the CEO's financial interests with short-to-medium term share price performance.

Positives

• CEO Ryan Saadi's beneficial ownership increased to 64.5%, indicating strong alignment with shareholder interests.
• The grant of 8,000,000 restricted shares as compensation for the CEO's service demonstrates continued commitment to long-term leadership.
• The restricted stock award includes voting rights, allowing the CEO to maintain influence over company decisions.

Negatives

• CEO Ryan Saadi sold 1,438,206 shares in an open market transaction on June 9, 2025, which could be perceived negatively by investors.
• The newly granted restricted shares have a long vesting period, with the first installment not vesting until June 27, 2032.

Risks

• Unvested restricted shares are subject to forfeiture if the CEO's service terminates for reasons other than death or disability.
• The CEO's restricted shares are subject to mandatory repayment or forfeiture if the Company determines he engaged in "Conduct Detrimental to the Company," including serious misconduct, breach of agreements, or engaging in "Conflicting Activities" (working for a direct competitor, soliciting employees, or soliciting clients).
• The value of the restricted stock is subject to the company's share price performance over a long vesting period.

Future Outlook

The filing primarily details changes in beneficial ownership and compensation, not forward-looking business guidance. It mentions the vesting schedule for restricted stock extending to 2032, indicating a long-term retention strategy for the CEO.

Industry Context

This filing, a Schedule 13D amendment, primarily focuses on changes in beneficial ownership and executive compensation for Tevogen Bio Holdings Inc. It does not provide information to analyze broader industry trends or competitive landscape. The company operates in the biotechnology sector, where executive compensation often includes significant equity components to align long-term interests.

Comparison to Industry Standards

• A 64.5% beneficial ownership stake for a CEO is exceptionally high, indicating significant control and alignment, which is higher than typical CEO ownership percentages in most publicly traded companies, especially larger ones. For example, in established biotech firms, CEO ownership rarely exceeds 10-20% unless it's a founder-led company post-IPO.
• The grant of 8,000,000 restricted shares as compensation is substantial, reflecting a common practice in the biotech industry to incentivize long-term performance and retention through equity awards. However, the seven-year cliff vesting for the first tranche (starting June 27, 2032) is unusually long compared to typical 3-5 year vesting schedules seen in most public companies, which could be a mechanism for extreme long-term retention or a reflection of the company's early stage post-IPO.
• The open market sale by the CEO, while not uncommon, can sometimes be viewed with caution by investors, especially when coupled with a new grant. The volume of 1.43 million shares is significant relative to the company's total outstanding shares.

Corporate Governance

Related Party Transactions

• Grant of 8,000,000 restricted shares to Ryan Saadi, the CEO, as compensation.
• Shares held by Dr. Saadi's spouse are included in shared voting and dispositive power.

Stakeholder Impact

• Shareholders: The CEO's increased beneficial ownership (64.5%) provides strong insider alignment, but the recent open market sale of 1.43 million shares could raise concerns about insider confidence. The long-term restricted stock grant ties the CEO's future compensation to the company's long-term performance.
• Employees: The filing does not directly impact general employees, but the CEO's compensation structure sets a precedent for executive incentives.

Next Steps

• Continued service of Ryan Saadi as CEO for vesting of restricted stock.
• Future annual vesting installments of the 8,000,000 restricted shares beginning June 27, 2032.

Key Dates

Recommendation

The filing presents a mixed signal. The CEO's substantial beneficial ownership (64.5%) and a new large restricted stock grant indicate strong long-term alignment and commitment. However, the simultaneous open market sale of over 1.4 million shares by the CEO could be interpreted negatively by the market, potentially signaling a lack of immediate confidence or a need for liquidity. The extremely long vesting period for the new grant (starting in 2032) means its positive impact is deferred. Given these conflicting signals, a "hold" recommendation is appropriate as investors should monitor future insider activity and company performance to assess the long-term implications of these actions.

Keywords

Tevogen Bio Holdings Inc., Ryan Saadi, Schedule 13D, Beneficial Ownership, Restricted Stock, CEO Compensation, Share Sale, Insider Trading, Corporate Governance, Biotechnology, Pharmaceutical